Bangalore-based Next Big Innovation Labs (NBIL) began in 2016 with the aim of impacting one billion people. Alok Medikepura Anil, co-founder and director, felt the vision could be fulfilled through 3D bio printing.
“As a tool, 3D bio printing helps lower the time-to-market medicines and drugs in the market. It will make a difference to the lives of people. Otherwise, drugs are developed over 10 years. Consequently, life science and R&D companies spend over $2bn for their development,” Anil said.
Efficiency will be seen in the early stages of drug development through 3D bio printing. 3D printing gives industries the ability to manufacture things at small scale and even with high levels of customisation. “In the pharma industry, 7,000 new drugs and 2,500 novel therapies are being developed globally,” he pointed out.
It didn’t take him long to figure out that 3D bio printing has diverse applications. This line of thinking led Anil to create a bio printing...